Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers
- PMID: 1590680
- PMCID: PMC189242
- DOI: 10.1128/AAC.36.1.144
Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers
Abstract
The pharmacokinetics of cefprozil were determined with 12 volunteers (8 received cefprozil and 4 received a placebo) after oral administration of 500 mg every 12 h over an 8-day period in a randomized, double-blind, placebo-controlled design. Concentrations in serum and urine were measured by high-pressure liquid chromatography and bioassay. The pharmacokinetic parameters were calculated on the basis of an open one-compartment model. The mean maximum concentration in serum on day 1 was 11.5 +/- 2.6 mg/liter, and the time to reach maximum concentration was 122.3 +/- 30 min after administration. Bioavailability parameters (area under the concentration-time curve from zero to infinity, maximum concentration of the drug in serum, and urinary recovery) indicated an excellent absorption. No accumulation over the 8-day period was registered. Cefprozil had a short biological elimination half-life of 58 +/- 10 min and a renal clearance of 210 +/- 51 ml/min, indicating high rates of renal excretion and tubular secretion. Analysis of the fecal flora showed an ecological impact of cefprozil on the intestinal microflora, such as a moderate decrease in enterobacteria and a slight increase in enterococci, staphylococci, and bacteroides during the study. The number of all bacterial species was already normalized 4 days after the administration period. The tolerance of cefprozil proved to be excellent; only a slight and reversible increase of liver enzymes (in two volunteers), mild cephalalgia, tiredness, and soft stool were registered during the 8-day period. Cefprozil had excellent absorption, no accumulation over an 8-day period, and only a limited impact on the intestinal microflora.
Similar articles
-
Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers.J Antimicrob Chemother. 1992 Sep;30(3):365-75. doi: 10.1093/jac/30.3.365. J Antimicrob Chemother. 1992. PMID: 1452502 Clinical Trial.
-
Absolute bioavailability of cefprozil after oral administration in beagles.Antimicrob Agents Chemother. 1992 Mar;36(3):687-9. doi: 10.1128/AAC.36.3.687. Antimicrob Agents Chemother. 1992. PMID: 1622187 Free PMC article.
-
Phase I study of multiple-dose cefprozil and comparison with cefaclor.Antimicrob Agents Chemother. 1990 Jun;34(6):1198-203. doi: 10.1128/AAC.34.6.1198. Antimicrob Agents Chemother. 1990. PMID: 2393281 Free PMC article. Clinical Trial.
-
Pharmacology and pharmacokinetics of cefprozil.Clin Infect Dis. 1992 Jun;14 Suppl 2:S184-8; discussion S195-6. doi: 10.1093/clinids/14.supplement_2.s184. Clin Infect Dis. 1992. PMID: 1617036 Review.
-
Comparative microbiological activity and pharmacokinetics of cefprozil.Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):839-45. doi: 10.1007/BF02111350. Eur J Clin Microbiol Infect Dis. 1994. PMID: 7889957 Review.
Cited by
-
Cefazolin as a predictor of urinary cephalosporin activity in indicated Enterobacterales.J Clin Microbiol. 2024 Apr 10;62(4):e0078821. doi: 10.1128/jcm.00788-21. Epub 2024 Mar 8. J Clin Microbiol. 2024. PMID: 38457194 Free PMC article. Review.
-
The initial state of the human gut microbiome determines its reshaping by antibiotics.ISME J. 2016 Mar;10(3):707-20. doi: 10.1038/ismej.2015.148. Epub 2015 Sep 11. ISME J. 2016. PMID: 26359913 Free PMC article.
-
Role of cephalosporins in the era of Clostridium difficile infection.J Antimicrob Chemother. 2017 Jan;72(1):1-18. doi: 10.1093/jac/dkw385. Epub 2016 Sep 22. J Antimicrob Chemother. 2017. PMID: 27659735 Free PMC article. Review.
-
Effect of ceftibuten on the normal intestinal microflora.Infection. 1993 Nov-Dec;21(6):373-5. doi: 10.1007/BF01728916. Infection. 1993. PMID: 8132366
-
Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states.Front Pharmacol. 2022 Oct 5;13:1012294. doi: 10.3389/fphar.2022.1012294. eCollection 2022. Front Pharmacol. 2022. PMID: 36278160 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources